礼来EBGLYSS成为首个在6个月至18岁中重度特应性皮炎患者中取得积极3期结果的选择性IL-13抑制剂

投资观察
Mar 16

礼来公司宣布,其药物EBGLYSS(lebrikizumab-lbkz)在针对6个月至18岁中重度特应性皮炎患者的3期临床试验中取得积极成果。该药是首个且唯一一个在此年龄段患者中展现出显著疗效的选择性IL-13抑制剂。

临床试验数据显示,在第16周时,有63%的受试者达到了EASI-75(湿疹面积和严重程度指数改善75%)的主要终点。同时,44%的患者实现了研究者总体评估(IGA)分数达到0或1(即皮损完全清除或几乎清除)。

EBGLYSS的安全性特征与先前的研究结果一致,未报告有注射部位疼痛的情况发生。

礼来计划将这些数据提交给美国及全球监管机构,以寻求更新该药物的标签适应症。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10